Accuray (ARAY) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
9 Nov, 2026Executive summary
FY23 revenue rose 4% YoY to $447.6M, but gross margin fell to 34.4% from 37.2%; operating income declined to $2.4M and net loss widened to $9.3M.
Net orders increased to $182.9M from $167.3M and book-to-bill was 1.3, while year-end backlog fell to $510.6M from $563.7M.
Financial highlights
Product revenue increased 9% to $233.2M; services revenue was $214.4M, down 0% as reported. FX reduced product revenue by $7.0M and service revenue by $10.8M.
Gross profit declined 4% to $154.0M; product gross profit fell 9% to $79.6M, while services gross profit rose 3% to $74.4M.
Operating expenses were nearly flat at $151.6M; operating income was $2.4M vs. $8.1M, and net loss was $9.3M vs. $5.3M.
FY23 included $2.7M in cash restructuring charges and a $2.0M bad-debt reserve tied to a U.S. customer bankruptcy.
Cash from operations was $15.5M vs. $2.4M used in FY22; cash and cash equivalents were $89.4M at June 30, 2023.
Outlook and guidance
Cash resources and anticipated cash flows were expected to fund operations for at least 12 months, based on available cash, debt facilities, the business plan and revenue prospects.
Higher material, freight and logistics costs were expected to pressure gross margins and net income through at least FY24, potentially longer.
NMPA clearance for the China JV’s locally branded Class B device was expected in H1 CY24, with orders anticipated shortly thereafter.
Latest events from Accuray
- FY13 system-sales weakness and MLC delays drove losses despite service growth.ARAY
Q4 2013 - Revenue and orders rebounded; adjusted EBITDA turned positive, but execution risks remained.ARAY
Q4 2014 - Record Q4 orders and constant-currency gains were offset by FX pressure and execution risks.ARAY
Q4 2015 - Record backlog and $24.6M adjusted EBITDA marked progress despite a $25.5M net loss.ARAY
Q4 2016 - Revenue and margin improved in FY18, but net orders weakened as cancellations and age-outs rose.ARAY
Q4 2018 - Record backlog and Radixact demand met lower revenue, weaker margins and continued losses.ARAY
Q4 2017 - TomoTherapy-led growth lifted revenue, but losses, cash use and conversion risks persisted.ARAY
Q4 2019 - Profitability returned, but COVID-19 delayed deliveries and backlog conversion.ARAY
Q4 2020 - Revenue grew 3%, but debt costs and COVID delays drove a $6.3m net loss.ARAY
Q4 2021